Long Acting Injectable Medications Market Size & CAGR (2023-2031)
The Long Acting Injectable Medications Market is expected to register a CAGR of 10.4% from 2023 to 2031, with a market size expanding from US$ XX million in 2023 to US$ XX Million by 2031.
The report is segmented by Type (First Generation, Second Generation). Futher, it is segmented based on End Use (Schizophrenia, Contraception, HIV, Others). The global analysis is further broken-down at regional level and major countries. The report offers the value in USD for the above analysis and segments.
Purpose of the ReportThe report Long Acting Injectable Medications Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Long Acting Injectable Medications Market Segmentation
Type- First Generation
- Second Generation
- Schizophrenia
- Contraception
- HIV
- Others
Strategic Insights
Long Acting Injectable Medications Market Growth Drivers- Increased Adherence of Patients: Long acting injectables significantly increase patient adherence to regimens in chronic treatments as it decreases the dosing frequency compared to oral medication.
- Advancements in Technology: Market growth is driven forward by innovation in the drug delivery system, allowing the sustained release of formulations that better improves therapeutic efficacy and outcome for patients.
- Increasing Prevalence of Chronic Conditions: The constantly growing prevalence of chronic diseases, like schizophrenia and diabetes, is increasing demand for long-acting injectable medications, which offer effective management options.
- Increasing Trends on Injectable Antipsychotics: The recent trend followed is the increased use of injectable antipsychotics, which can be a good alternative to oral drugs, especially in the treatment of schizophrenia.
- Aligning with Patient-Centric Solutions: There is an increasing incorporation of patient-centric approaches by drug manufacturers. They are developing products that could reflect individual needs and improve treatment experiences.
- Integration of Digital Health Technologies: Long-acting injectable therapies are now being improved through incorporating digital health technologies such as telemedicine and mobile health applications. This will continue to improve the management of long acting injectables, enhancing patient engagement and monitoring.
- Regulatory Assistance for New Formulations: Regulatory agencies are streamlining the process for innovative long-acting injectable preparations, such that new treatments become increasingly available to capture this emerging market.
- Development of Combination Therapies: Long-acting injectable combinations offer possibilities for combination therapies that can hopefully strengthen the treatment outcome for complex conditions.
- Research and Development Investments: Novel long acting formulation R&D investments could result in the development of new treatments addressing unmet medical needs in various therapeutic areas.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Long Acting Injectable Medications Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Long Acting Injectable Medications Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Eli Lilly and Johnson and Johnson are some of the major players operating in the market.
The report provides an extensive qualitative and quantitative analysis of the current trends and future estimations of the global long acting injectable medications market from 2021 to 2031, and it also determines the prevailing opportunities.
Asia Pacific region accounted for the highest CAGR in the long acting injectable medications market.
North America region dominated the long acting injectable medications market in 2023.
The major factors driving the long acting injectable medications market are:
1. Increased Adherence of Patients.
2. Increasing Prevalence of Chronic Conditions.
The Long Acting Injectable Medications Market is estimated to witness a CAGR of 10.4% from 2023 to 2031
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Long Acting Injectable Medications Market - By Type
1.3.2 Long Acting Injectable Medications Market - By End Use
1.3.3 Long Acting Injectable Medications Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. LONG ACTING INJECTABLE MEDICATIONS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. LONG ACTING INJECTABLE MEDICATIONS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. LONG ACTING INJECTABLE MEDICATIONS MARKET - GLOBAL MARKET ANALYSIS
6.1. LONG ACTING INJECTABLE MEDICATIONS - GLOBAL MARKET OVERVIEW
6.2. LONG ACTING INJECTABLE MEDICATIONS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. LONG ACTING INJECTABLE MEDICATIONS MARKET - REVENUE AND FORECASTS TO 2028 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. FIRST GENERATION
7.3.1. Overview
7.3.2. First Generation Market Forecast and Analysis
7.4. SECOND GENERATION
7.4.1. Overview
7.4.2. Second Generation Market Forecast and Analysis
8. LONG ACTING INJECTABLE MEDICATIONS MARKET - REVENUE AND FORECASTS TO 2028 - END USE
8.1. OVERVIEW
8.2. END USE MARKET FORECASTS AND ANALYSIS
8.3. SCHIZOPHRENIA
8.3.1. Overview
8.3.2. Schizophrenia Market Forecast and Analysis
8.4. CONTRACEPTION
8.4.1. Overview
8.4.2. Contraception Market Forecast and Analysis
8.5. HIV
8.5.1. Overview
8.5.2. HIV Market Forecast and Analysis
8.6. OTHERS
8.6.1. Overview
8.6.2. Others Market Forecast and Analysis
9. LONG ACTING INJECTABLE MEDICATIONS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Long Acting Injectable Medications Market Overview
9.1.2 North America Long Acting Injectable Medications Market Forecasts and Analysis
9.1.3 North America Long Acting Injectable Medications Market Forecasts and Analysis - By Type
9.1.4 North America Long Acting Injectable Medications Market Forecasts and Analysis - By End Use
9.1.5 North America Long Acting Injectable Medications Market Forecasts and Analysis - By Countries
9.1.5.1 United States Long Acting Injectable Medications Market
9.1.5.1.1 United States Long Acting Injectable Medications Market by Type
9.1.5.1.2 United States Long Acting Injectable Medications Market by End Use
9.1.5.2 Canada Long Acting Injectable Medications Market
9.1.5.2.1 Canada Long Acting Injectable Medications Market by Type
9.1.5.2.2 Canada Long Acting Injectable Medications Market by End Use
9.1.5.3 Mexico Long Acting Injectable Medications Market
9.1.5.3.1 Mexico Long Acting Injectable Medications Market by Type
9.1.5.3.2 Mexico Long Acting Injectable Medications Market by End Use
9.2. EUROPE
9.2.1 Europe Long Acting Injectable Medications Market Overview
9.2.2 Europe Long Acting Injectable Medications Market Forecasts and Analysis
9.2.3 Europe Long Acting Injectable Medications Market Forecasts and Analysis - By Type
9.2.4 Europe Long Acting Injectable Medications Market Forecasts and Analysis - By End Use
9.2.5 Europe Long Acting Injectable Medications Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Long Acting Injectable Medications Market
9.2.5.1.1 Germany Long Acting Injectable Medications Market by Type
9.2.5.1.2 Germany Long Acting Injectable Medications Market by End Use
9.2.5.2 France Long Acting Injectable Medications Market
9.2.5.2.1 France Long Acting Injectable Medications Market by Type
9.2.5.2.2 France Long Acting Injectable Medications Market by End Use
9.2.5.3 Italy Long Acting Injectable Medications Market
9.2.5.3.1 Italy Long Acting Injectable Medications Market by Type
9.2.5.3.2 Italy Long Acting Injectable Medications Market by End Use
9.2.5.4 Spain Long Acting Injectable Medications Market
9.2.5.4.1 Spain Long Acting Injectable Medications Market by Type
9.2.5.4.2 Spain Long Acting Injectable Medications Market by End Use
9.2.5.5 United Kingdom Long Acting Injectable Medications Market
9.2.5.5.1 United Kingdom Long Acting Injectable Medications Market by Type
9.2.5.5.2 United Kingdom Long Acting Injectable Medications Market by End Use
9.2.5.6 Rest of Europe Long Acting Injectable Medications Market
9.2.5.6.1 Rest of Europe Long Acting Injectable Medications Market by Type
9.2.5.6.2 Rest of Europe Long Acting Injectable Medications Market by End Use
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Long Acting Injectable Medications Market Overview
9.3.2 Asia-Pacific Long Acting Injectable Medications Market Forecasts and Analysis
9.3.3 Asia-Pacific Long Acting Injectable Medications Market Forecasts and Analysis - By Type
9.3.4 Asia-Pacific Long Acting Injectable Medications Market Forecasts and Analysis - By End Use
9.3.5 Asia-Pacific Long Acting Injectable Medications Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Long Acting Injectable Medications Market
9.3.5.1.1 Australia Long Acting Injectable Medications Market by Type
9.3.5.1.2 Australia Long Acting Injectable Medications Market by End Use
9.3.5.2 China Long Acting Injectable Medications Market
9.3.5.2.1 China Long Acting Injectable Medications Market by Type
9.3.5.2.2 China Long Acting Injectable Medications Market by End Use
9.3.5.3 India Long Acting Injectable Medications Market
9.3.5.3.1 India Long Acting Injectable Medications Market by Type
9.3.5.3.2 India Long Acting Injectable Medications Market by End Use
9.3.5.4 Japan Long Acting Injectable Medications Market
9.3.5.4.1 Japan Long Acting Injectable Medications Market by Type
9.3.5.4.2 Japan Long Acting Injectable Medications Market by End Use
9.3.5.5 South Korea Long Acting Injectable Medications Market
9.3.5.5.1 South Korea Long Acting Injectable Medications Market by Type
9.3.5.5.2 South Korea Long Acting Injectable Medications Market by End Use
9.3.5.6 Rest of Asia-Pacific Long Acting Injectable Medications Market
9.3.5.6.1 Rest of Asia-Pacific Long Acting Injectable Medications Market by Type
9.3.5.6.2 Rest of Asia-Pacific Long Acting Injectable Medications Market by End Use
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Long Acting Injectable Medications Market Overview
9.4.2 Middle East and Africa Long Acting Injectable Medications Market Forecasts and Analysis
9.4.3 Middle East and Africa Long Acting Injectable Medications Market Forecasts and Analysis - By Type
9.4.4 Middle East and Africa Long Acting Injectable Medications Market Forecasts and Analysis - By End Use
9.4.5 Middle East and Africa Long Acting Injectable Medications Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Long Acting Injectable Medications Market
9.4.5.1.1 South Africa Long Acting Injectable Medications Market by Type
9.4.5.1.2 South Africa Long Acting Injectable Medications Market by End Use
9.4.5.2 Saudi Arabia Long Acting Injectable Medications Market
9.4.5.2.1 Saudi Arabia Long Acting Injectable Medications Market by Type
9.4.5.2.2 Saudi Arabia Long Acting Injectable Medications Market by End Use
9.4.5.3 U.A.E Long Acting Injectable Medications Market
9.4.5.3.1 U.A.E Long Acting Injectable Medications Market by Type
9.4.5.3.2 U.A.E Long Acting Injectable Medications Market by End Use
9.4.5.4 Rest of Middle East and Africa Long Acting Injectable Medications Market
9.4.5.4.1 Rest of Middle East and Africa Long Acting Injectable Medications Market by Type
9.4.5.4.2 Rest of Middle East and Africa Long Acting Injectable Medications Market by End Use
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Long Acting Injectable Medications Market Overview
9.5.2 South and Central America Long Acting Injectable Medications Market Forecasts and Analysis
9.5.3 South and Central America Long Acting Injectable Medications Market Forecasts and Analysis - By Type
9.5.4 South and Central America Long Acting Injectable Medications Market Forecasts and Analysis - By End Use
9.5.5 South and Central America Long Acting Injectable Medications Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Long Acting Injectable Medications Market
9.5.5.1.1 Brazil Long Acting Injectable Medications Market by Type
9.5.5.1.2 Brazil Long Acting Injectable Medications Market by End Use
9.5.5.2 Argentina Long Acting Injectable Medications Market
9.5.5.2.1 Argentina Long Acting Injectable Medications Market by Type
9.5.5.2.2 Argentina Long Acting Injectable Medications Market by End Use
9.5.5.3 Rest of South and Central America Long Acting Injectable Medications Market
9.5.5.3.1 Rest of South and Central America Long Acting Injectable Medications Market by Type
9.5.5.3.2 Rest of South and Central America Long Acting Injectable Medications Market by End Use
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL LONG ACTING INJECTABLE MEDICATIONS MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. LONG ACTING INJECTABLE MEDICATIONS MARKET, KEY COMPANY PROFILES
12.1. ELI LILLY
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. ALKERMES
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. JOHNSON AND JOHNSON
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. ZOGENIX
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. DURECT
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. MAPI PHARMA
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. GSK
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. MEDINCELL
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. OAKWOOD LABS
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. NANOMI
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1. Eli Lilly
2. Alkermes
3. Johnson and Johnson
4. Zogenix
5. DURECT
6. Mapi Pharma
7. GSK
8. MedinCell
9. Oakwood Labs
10. Nanomi
11. Pharmathen
12. Kashiv BioSciences
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For